Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Axatilimab |
Trade Name | Niktimvo |
Synonyms | SNDX 6352|SNDX6352|UCB6352|SNDX-6352 |
Drug Descriptions |
Niktimvo (axatilimab) is a humanized monoclonal antibody against colony-stimulating factor-1 receptor (CSF-1R), which may enhance anti-tumor immune response (SITC Meeting, Nov 2017, abstract P505). Niktimvo (axatilimab) is FDA-approved for the treatment of chronic graft-versus-host disease (FDA.gov) |
DrugClasses | CSF1R Antibody 5 |
CAS Registry Number | 2155851-88-8 |
NCIT ID | C155813 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Axatilimab | Axatilimab | 0 | 2 |
Axatilimab + Azacitidine | Axatilimab Azacitidine | 0 | 1 |
Axatilimab + Durvalumab | Axatilimab Durvalumab | 0 | 2 |
Axatilimab + Nivolumab | Axatilimab Nivolumab | 0 | 1 |
Axatilimab + Olaparib | Axatilimab Olaparib | 0 | 1 |
Axatilimab + Paclitaxel + Retifanlimab | Axatilimab Paclitaxel Retifanlimab | 0 | 1 |
Axatilimab + Pembrolizumab | Axatilimab Pembrolizumab | 0 | 1 |